Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. More Details
Excellent balance sheet and fair value.
Share Price & News
How has Surface Oncology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SURF is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SURF's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: SURF underperformed the US Biotechs industry which returned 24.9% over the past year.
Return vs Market: SURF underperformed the US Market which returned 34.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Surface Oncology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIf You Had Bought Surface Oncology's (NASDAQ:SURF) Shares Three Years Ago You Would Be Down 47%
1 month ago | Simply Wall StIs Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Is Surface Oncology undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SURF's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SURF's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SURF is good value based on its PE Ratio (9.5x) compared to the US Biotechs industry average (22.7x).
PE vs Market: SURF is good value based on its PE Ratio (9.5x) compared to the US market (18x).
Price to Earnings Growth Ratio
PEG Ratio: SURF's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: SURF is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (2.8x).
How is Surface Oncology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SURF's earnings are forecast to decline over the next 3 years (-19.1% per year).
Earnings vs Market: SURF's earnings are forecast to decline over the next 3 years (-19.1% per year).
High Growth Earnings: SURF's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SURF's revenue (10.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SURF's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SURF's Return on Equity is forecast to be high in 3 years time
How has Surface Oncology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SURF has high quality earnings.
Growing Profit Margin: SURF became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SURF has become profitable over the past 5 years, growing earnings by 27.2% per year.
Accelerating Growth: SURF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SURF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).
Return on Equity
High ROE: SURF's Return on Equity (13.3%) is considered low.
How is Surface Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: SURF's short term assets ($179.0M) exceed its short term liabilities ($14.9M).
Long Term Liabilities: SURF's short term assets ($179.0M) exceed its long term liabilities ($40.8M).
Debt to Equity History and Analysis
Debt Level: SURF's debt to equity ratio (8.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SURF's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SURF's debt is well covered by operating cash flow (190.5%).
Interest Coverage: SURF's interest payments on its debt are well covered by EBIT (7.8x coverage).
What is Surface Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SURF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SURF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SURF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SURF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SURF's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rob Ross (47 yo)
Dr. Robert W. Ross, M.D., also known as Rob, is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Director at Obsidian Therapeutic. He served as Ch...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD1.12M) is about average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
Experienced Management: SURF's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: SURF's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SURF insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.3%.
Surface Oncology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Surface Oncology, Inc.
- Ticker: SURF
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$224.093m
- Shares outstanding: 43.43m
- Website: https://www.surfaceoncology.com
Number of Employees
- Surface Oncology, Inc.
- 50 Hampshire Street
- 8th Floor
- United States
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully h...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/04 22:59|
|End of Day Share Price||2021/08/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.